EP Wealth Advisors LLC Sells 170 Shares of Amgen Inc. (NASDAQ:AMGN)

view original post

EP Wealth Advisors LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 0.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 20,532 shares of the medical research company’s stock after selling 170 shares during the period. EP Wealth Advisors LLC’s holdings in Amgen were worth $4,965,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in shares of Amgen by 2.1% during the 4th quarter. BlackRock Inc. now owns 50,046,345 shares of the medical research company’s stock worth $11,258,926,000 after acquiring an additional 1,032,929 shares during the last quarter. Vanguard Group Inc. raised its position in Amgen by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 47,329,045 shares of the medical research company’s stock worth $11,445,110,000 after purchasing an additional 668,036 shares during the period. State Street Corp raised its position in Amgen by 1.2% in the 1st quarter. State Street Corp now owns 30,504,420 shares of the medical research company’s stock worth $7,376,579,000 after purchasing an additional 357,413 shares during the period. Charles Schwab Investment Management Inc. raised its position in Amgen by 1.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock worth $2,132,778,000 after purchasing an additional 94,565 shares during the period. Finally, Deutsche Bank AG raised its position in Amgen by 8.7% in the 4th quarter. Deutsche Bank AG now owns 5,660,218 shares of the medical research company’s stock worth $1,273,380,000 after purchasing an additional 453,750 shares during the period. 77.14% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AMGN. Morgan Stanley lifted their target price on shares of Amgen from $239.00 to $253.00 and gave the stock an “equal weight” rating in a research report on Friday, July 15th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 8th. Robert W. Baird reiterated an “underperform” rating and issued a $185.00 target price on shares of Amgen in a research report on Tuesday. Royal Bank of Canada lifted their target price on shares of Amgen from $224.00 to $236.00 in a research report on Friday, August 5th. Finally, Piper Sandler boosted their price objective on shares of Amgen from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $241.13.

Insider Buying and Selling

In related news, Director Robert Eckert sold 6,600 shares of the business’s stock in a transaction dated Thursday, August 18th. The shares were sold at an average price of $249.00, for a total transaction of $1,643,400.00. Following the sale, the director now owns 21,184 shares of the company’s stock, valued at $5,274,816. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director R Sanders Williams sold 200 shares of the business’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $249.96, for a total transaction of $49,992.00. Following the sale, the director now owns 5,301 shares of the company’s stock, valued at $1,325,037.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Eckert sold 6,600 shares of the company’s stock in a transaction that occurred on Thursday, August 18th. The stock was sold at an average price of $249.00, for a total transaction of $1,643,400.00. Following the completion of the transaction, the director now owns 21,184 shares in the company, valued at approximately $5,274,816. The disclosure for this sale can be found here. 0.46% of the stock is currently owned by insiders.

Amgen Trading Up 0.6 %

Shares of AMGN opened at $228.12 on Thursday. The firm’s 50-day moving average price is $246.02 and its 200-day moving average price is $243.53. The firm has a market capitalization of $122.03 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 2.00 and a beta of 0.56. The company has a current ratio of 1.53, a quick ratio of 1.17 and a debt-to-equity ratio of 14.76. Amgen Inc. has a 1-year low of $198.64 and a 1-year high of $258.45.

Amgen (NASDAQ:AMGNGet Rating) last announced its earnings results on Thursday, August 4th. The medical research company reported $4.65 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.25. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.53 billion. Amgen had a net margin of 24.92% and a return on equity of 218.34%. The company’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.38 EPS. Sell-side analysts anticipate that Amgen Inc. will post 17.45 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Thursday, August 18th were paid a dividend of $1.94 per share. This represents a $7.76 annualized dividend and a yield of 3.40%. The ex-dividend date was Wednesday, August 17th. Amgen’s payout ratio is currently 65.76%.

About Amgen

(Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts